Page last updated: 2024-08-24

darglitazone and Bone Loss, Osteoclastic

darglitazone has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brown, TA; Healy, DR; Ke, HZ; Li, M; Li, Y; Pan, LC; Robinson, BS; Simmons, HA	1

Other Studies

1 other study(ies) available for darglitazone and Bone Loss, Osteoclastic

Article	Year
Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone, 2006, Volume: 39, Issue:4 Topics: Adipogenesis; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Marrow Cells; Bone Resorption; Cells, Cultured; Dose-Response Relationship, Drug; Femur; Gene Expression; Male; Mice; Mice, Inbred C57BL; Organ Size; Osteoclasts; Osteogenesis; PPAR gamma; Thiazolidinediones; Time Factors; Tomography, X-Ray Computed	2006

Article

Year

Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.

Bone, 2006, Volume: 39, Issue:4

Topics: Adipogenesis; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Marrow Cells; Bone Resorption; Cells, Cultured; Dose-Response Relationship, Drug; Femur; Gene Expression; Male; Mice; Mice, Inbred C57BL; Organ Size; Osteoclasts; Osteogenesis; PPAR gamma; Thiazolidinediones; Time Factors; Tomography, X-Ray Computed

2006